Cryptosporidium parvum is a protozoan parasite that can cause severe diarrheal disease in humans and animals. Several antigens have been identified in this parasite, including Cp23, CpGP34, CP15-60, gp15, and Iowa II A.

Cp23 is an immunodominant antigen that is expressed on the surface of sporozoites, the infectious form of the parasite. It has been shown to play an important role in the invasion of host cells by the parasite, making it a potential target for vaccine development.

CpGP34 is another surface antigen that has been shown to be important in the invasion process. It is expressed on both sporozoites and merozoites, the replicating form of the parasite. Studies have shown that antibodies against CpGP34 can block invasion by the parasite, suggesting that it may also be a potential target for vaccine development.

CP15-60 is a 15 kDa sporozoite surface antigen that has been shown to induce a protective immune response in mice. It is also expressed on the surface of oocysts, the environmentally resistant form of the parasite that is shed in feces and can infect new hosts.

Gp15 is a glycoprotein that is expressed on the surface of sporozoites and oocysts. It is thought to be involved in the attachment of the parasite to host cells and has been shown to induce a protective immune response in mice.

Iowa II A is a surface protein that contains two conserved cysteines and is expressed on the surface of sporozoites. Its function is not yet fully understood, but it has been shown to be recognized by antibodies in infected individuals.

Understanding the biology and immunology of Cryptosporidium parvum antigens is important for the development of effective treatments and vaccines. These antigens may also serve as diagnostic markers for the detection of the parasite in clinical and environmental samples.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.